Biotech · Public company · Berkeley, CA, US

Caribou Biosciences, Inc.

Ticker CRBU · SEC CIK 0001619856

Track this companyFree. Adds Caribou Biosciences, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials43 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

CB-010Phase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
CB-011Phase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
CB-012Phase 1 · Acute Myeloid Leukemia, in RelapseClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
Caribou-sponsored investigational therapyLymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPHASE1 · TERMINATED · started Feb 8, 2024ClinicalTrials.gov NCT06128044 · fetched Nov 12, 2026
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaPHASE1 · RECRUITING · started Feb 6, 2023ClinicalTrials.gov NCT05722418 · fetched Nov 12, 2026
Long-Term Follow-up StudyENROLLING_BY_INVITATION · started Mar 16, 2022ClinicalTrials.gov NCT05332054 · fetched Nov 12, 2026
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)PHASE1 · ACTIVE_NOT_RECRUITING · started May 26, 2021ClinicalTrials.gov NCT04637763 · fetched Nov 12, 2026